戻る
Therapeutic Solutions International Inc (TSOI) 収入
TSOI 株価推移チャート
TSOI 収入
Therapeutic Solutions International Inc
$0
0%
$0
終値： Mar 24, 16:00:00 GMT-4
$0
0%
$0
アフターマーケット：Mar 24, 20:00:00 GMT-4
Earnings FAQ
TSOIの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Therapeutic Solutions International Inc TSOIの前四半期の収益はどうでしたか？
Therapeutic Solutions International Incの収益見積もりはいくらですか？
Therapeutic Solutions International Incの収益品質スコアはどれくらいですか？
Therapeutic Solutions International Incはいつ収益を報告しますか？
Therapeutic Solutions International Incの予想収益はいくらですか？
Therapeutic Solutions International Incは収益予想を上回りましたか？
主要データ
前終値
$0.0001
始値
$0.0001
当日レンジ
$0.0001 - $0.0001
52週レンジ
$0.0001 - $0.0003
取引高
262.5K
平均取引高
0
配当利回り
--
1株当たり利益(TTM)
-0.00
時価総額
$512.2K
TSOIとは何ですか？
Therapeutic Solutions International, Inc. engages in the provision of immune modulation for the treatment of several specific diseases. The company is headquartered in Elk City, Idaho and currently employs 3 full-time employees. The company went IPO on 2008-06-09. The firm is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, and traumatic brain injury (TBI), and for daily health. Its flagship product, QuadraMune, is a multi-patented synergistic blend of pterostilbene, sulforaphane, epigallocatechin gallate, and thymoquinone. Its synergistic blend of ingredients helps the immune system fight off common and complex ailments and promotes healthy T Cell activity. The company has developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body's natural killer (NK) cells. The company has obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic traumatic encephalopathy (CTE), TBI, and lung pathology.